aspartame/cannabidiol (JW-100) / Jupiter Wellness - LARVOL DELTA

WHO declares artificial sweetener aspartame a potential carcinogen (Medical News Today) - "Dr. Misagh Karimi...told Medical News Today it's important to understand when a product falls into one of the IARC's four categories."

Media quote

Aspartame Declared Possible Carcinogen by World Health Organization (Cleveland Clinic) - "'When we think about the risk of aspartame, we have to really put it in perspective,' said Dale Shepard, MD...'The artificial sweetener is now considered a possible carcinogen by the WHO's cancer research agency. But there are things people do and eat that are known to be carcinogenic, like the excessive consumption of alcohol and smoking.'"

Media quote

Aspartame listed as 'possible carcinogen,' regulators still consider it safe in moderation (ABC News) - "The American Cancer Society welcomes the call for more research into aspartame, Dr. William Dahut...told ABC News. 'As data evolves, I do think people should be aware that recommendations could change,' he said."

Media quote

Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Applied Biology, Inc. | N=200 ➔ 0 | Trial completion date: Apr 2024 ➔ Dec 2022 | Recruiting ➔ Withdrawn | Trial primary completion date: Dec 2023 ➔ Dec 2022

Enrollment change • Head-to-Head • Trial completion date • Trial primary completion date • Trial withdrawal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Applied Biology, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Comparison of JW-100 and EUCRISA for the Treatment of Eczema (clinicaltrials.gov) - P3 | N=200 | Not yet recruiting | Sponsor: Applied Biology, Inc. | Trial completion date: Apr 2022 ➔ Apr 2024 | Trial primary completion date: Feb 2022 ➔ Dec 2023

Head-to-Head • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Comparison of JW-100 and EUCRISA® (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: Applied Biology, Inc. | N=184 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Head-to-Head • Trial withdrawal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology